scispace - formally typeset
V

Vladimir Brusic

Researcher at Nazarbayev University

Publications -  224
Citations -  14646

Vladimir Brusic is an academic researcher from Nazarbayev University. The author has contributed to research in topics: Epitope & Antigen. The author has an hindex of 50, co-authored 212 publications receiving 13727 citations. Previous affiliations of Vladimir Brusic include Griffith University & Harvard University.

Papers
More filters
Journal ArticleDOI

Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells

TL;DR: Data support the use of this Melan-A/MART-1 DR4-restricted melanoma epitope in future immunotherapeutic trials designed to generate, augment, and quantitate specific CD4+ T cell responses against melanoma in vivo.
Journal ArticleDOI

ANTIMIC: a database of antimicrobial sequences.

TL;DR: A comprehensive database of known and putative AMPs, which contains approximately 1700 of these peptides, is developed and integrated with tools to facilitate efficient extraction of data and their analysis at molecular level, as well as search for new AMPs.
Journal ArticleDOI

Methods for prediction of peptide binding to MHC molecules: A comparative study

TL;DR: The ability of bioinformatic methods to reliably predict MHC binding peptides, and thereby potential T-cell epitopes, has major implications for clinical immunology, particularly in the area of vaccine design.
Journal ArticleDOI

MHCPEP, a database of MHC-binding peptides: update 1996.

TL;DR: MHCPEP is a curated database comprising over 9000 peptide sequences known to bind MHC molecules that can be accessed via Internet using WWW, FTP or Gopher.
Journal ArticleDOI

MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides

TL;DR: Testing results show that MULTIPRED is both sensitive and specific and it has good predictive ability, and can be used for the mapping of promiscuous T-cell epitopes as well as the regions of high concentration of these targets—termed T- cell epitope hotspots.